SAB Biotherapeutics (SABSW) Stock: Why It's Down Today
Updated Oct 20, 2026, 4:00 PM ET · closing price
- Closed at $0.01, -15.28% vs the prior close of $0.01.
- Volume 2.72K shares, 194.2x its 50-day average (heavy).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
SABSW slides 15.3% to $0.01 on 194.2x normal volume. Closed at $0.01, -15.28% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.05.
SABSW daily analysis — what happened
A plain-English, data-only note for every US trading day (today's note updates every 2 hours while the market is open). Newest first; older days stay archived below.
Oct 20, 2026 — SABSW slides 15.3% to $0.01 on 194.2x normal volume
- Closed at $0.01, -15.28% vs the prior close of $0.01. Day range $0.01–$0.01, opened at $0.05.
- Volume was 2.72K shares, 194.2x its 50-day average of 14 — unusually heavy trading.
- 52-week range $0.01–$0.01; today's close sits at 0% of that range, 18.7% below the 52-week high.
SABSW bull case vs bear case (from the data)
- Latest fiscal-year net income: profit of $13.27M.
- Annual revenue fell 100.0% in the latest fiscal year (SEC XBRL).
- Share count up 773.9% in a year (dilution).
- High volatility: average daily move of 15.3% over 20 sessions.
- Thin trading (under $2M a day on average) can mean wide bid/ask spreads.
SABSW latest news & SEC filings
Every SEC filing by or about SABSW in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kropotova Alexandra had withheld for taxes 473 shares on Sep 17, 2026; now holds 41,853
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 21, 2026 · Form 424B3 — Prospectus / supplement for an offering or resale
Prospectus / supplement for an offering or resale
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 12, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 10, 2026 · Form SCHEDULE 13D/A — Update to a 13D 5%+ stake disclosure
Update to a 13D 5%+ stake disclosure
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 6, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$22.49M (prior year -$10.11M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.28 (prior year -$1.09) (loss narrowed vs Jun 30, 2025)
Jul 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Jun 26, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Things to know before you trade SABSW
- Last results release: Mar 29, 2024 (8-K Item 2.02). Previous ones: Mar 31, 2023, Nov 22, 2021. Based on that rhythm, the next report is likely around Jun 28, 2024 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 15.28% (largest 15.3%). That is a volatile stock.
- Liquidity: about 1.37K shares (≈$8) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.01 vs a range of $0.01–$0.01 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Oct 13, 2026; 10-Q Aug 6, 2026; 8-K Jul 7, 2026.
- Share count: 90.99M shares outstanding (Aug 3, 2026), +773.9% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
SABSW market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 20, 2026 | 0.05 | 0.01 | 0.01 | 0.01 | 2.72K |
| Oct 16, 2026 | 0.05 | 0.01 | 0.01 | 0.01 | 14 |
About SAB Biotherapeutics
SAB Biotherapeutics (SABSW) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in MIAMI BEACH, FL. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1833214.
SABSW board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Helen K. Ellias | Director | Dec 18, 2025 |
| Scott Giberson | Director | Dec 18, 2025 |
| Rita Jain | Director | Jan 7, 2026 |
| David Link | Director | Dec 18, 2025 |
| Erick Lucera | Director | Dec 18, 2025 |
| Andrew Moin | Director | Oct 1, 2025 |
| John Petry | Director | Oct 1, 2025 |
| William James Polvino | Director | Dec 18, 2025 |
| Samuel J Reich | CEO | Feb 5, 2026 |
| Jay S Skyler | Director | Dec 18, 2025 |
| Capital (Master), L.P. Sessa | Director | Oct 1, 2025 |
| Capital Gp, Llc Sessa | Director | Oct 1, 2025 |
| Capital Im Gp, Llc Sessa | Director | Oct 1, 2025 |
| Capital Im, L.P. Sessa | Director | Oct 1, 2025 |
| Eddie Joe Sullivan | PRESIDENT | Feb 5, 2026 |
| David Zaccardelli | Director | Jan 7, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christoph Lawrence Bausch | CHIEF OPERATING OFFICER | Feb 5, 2026 |
| Alexandra Kropotova | CHIEF MEDICAL OFFICER | Sep 18, 2026 |
| Samuel J Reich | CEO | Feb 5, 2026 |
| Eddie Joe Sullivan | PRESIDENT | Feb 5, 2026 |
| Lucy To | See Remarks | Feb 5, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
SABSW financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $0 | $13.27M | -0.79 | $-44.78M |
| Dec 31, 2024 | $1.32M | $-34.11M | -3.68 | $-34.29M |
| Dec 31, 2023 | $2.24M | $-42.19M | -7.64 | $-25.12M |
| Dec 31, 2022 | $23.90M | $-18.74M | -4.31 | $-23.46M |
| Dec 31, 2021 | $60.88M | $-17.14M | -0.63 | $1.99M |
Latest balance sheet: total assets $238.21M, total liabilities $23.43M, cash $8.27M (as of Jun 30, 2026).
SABSW earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Mar 29, 2024 | 8-K Item 2.02 (results) | — |
| Mar 31, 2023 | 8-K Item 2.02 (results) | — |
| Nov 22, 2021 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Biogen (BIIB)Halozyme Therapeutics (HALO)Vaxcyte (PCVX)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Space Exploration Technologies (SPCX)Tesla (TSLA)Sandisk (SNDK)Apple (AAPL)AMD (AMD)Microsoft (MSFT)Intel (INTC)Amazon (AMZN)
More on SABSW
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 20, 2026, 4:00 PM ET. Filings: SEC EDGAR. Refreshed every 2 hours during US market hours.